Study S002760

To Assess the Pharmacokinetic (PK) Differences of GZR18 Injection Between Subjects With Renal Impairment and Those With Normal Renal Function, Providing a Basis for Establishing a Clinical Dosing Regimen for Patients With Renal Impairment

ClinicalTrials.gov record

Registration

Registration: NCT07141030
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: RECRUITING
Enrollment: 32
Start: 2025-04-11
Primary completion: 2025-10-09
Lead sponsor: Gan & Lee Pharmaceuticals.
Conditions: Obesity/Overweight
Interventions: DRUG:GZR18 injection
Results posted: FALSE

Registered primary outcomes

Cmax:Maximum plasma concentration [through study completion, an average of 36 days]
AUC0-last:Area under the plasma concentration-time curve at 0 h to last observation time-point after a single dose. [through study completion, an average of 36 days]
AUC0-inf:Area under the plasma concentration-time curve at 0 h to infinity after a single dose. [through study completion, an average of 36 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.